A rapid variant-tolerant reverse transcription loop-mediated isothermal amplification assay for the point of care detection of HIV-1. Issue 17 (29th July 2021)

• Record Type: Journal Article
• Authors: Li, Yingxue; Chen, Xin; Zhao, Yongjuan; Wan, Zhenzhou; Zeng, Yi; Ma, Yingying; Zhou, Lianqun; Xu, Gaolian; Reboud, Julien; Cooper, Jonathan M.; Zhang, Chiyu
• Is Part Of: Analyst. Volume 146:Issue 17(2021)
• Page Start: 5347
• Page End: 5356
• Publication Date: 2021-07-29
• Subjects: Chemistry, Analytic -- Periodicals; 543
• DOI: 10.1039/d1an00598g
• Languages: English
• ISSNs: 0003-2654

Abstract

Abstract : Human immunodeficiency virus (HIV) rapid variant mutations challenges diagnostic assays. Our variant-tolerant isothermal nucleic acid based amplification technique enables reliable detection at the point-of-care. Abstract : Human immunodeficiency virus (HIV) continues to be a major burden on public health globally with on-going increases in the number of new infections each year. Rapid and sensitive point-of-care tests allow timely interventions and are essential to control the spread of the disease. However the highly variable nature of the virus, resulting in the evolution of many subtypes and inter-subtype recombinants, poses important challenges for its diagnosis. Here we describe a variant-tolerant reverse-transcription RT-LAMP amplification of the virus's INT gene, providing a simple to use, rapid (<30 min) in vitro point-of-care diagnostic test with a limit of detection <18 copies/reaction. The assay was first validated in clinical studies of patient samples, using both established RT-LAMP and RT-qPCR assays for reference, with results showing that this new variant-tolerant HIV-1 RT-LAMP diagnostic test is highly sensitive without compromising its high specificity for HIV-1 subtypes. The diagnostic test was subsequently configured within an easy-to-read paper microfluidic lateral flow test and was validated clinically using patient samples, demonstrating its future potential for use in timely, effective, low cost HIV diagnostics in global regions where healthcare resources may be limited.